ALT - Multiplikator Forward P/S Altimmune, Inc.

The estimated forward P/S for Altimmune, Inc. (ALT) reflects the impact of pemvidutide development for obesity treatment and compliance with environmental regulations regarding laboratory emission filtration. The 10376.90 metric confirms the current business valuation, which relies on sustained demand, although it remains dependent on the stability of global supply chains and patent protection amid geopolitical tensions.

ALT Altimmune: Rasio kapitalisasi marang dodolan sing dikarepake ing interval 04.07.2022 - 13.11.2026

Rincian metrik lan analitis perusahaan Altimmune Pharma (ALT)

- rega pasar lan target rega analis:

Bagan rega Altimmune|ALT - Bagan rega target

- statistik kapitalisasi pasar:

Kapitalisasi pasar Altimmune Pharma|ALT - Rega Tumbas Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham Altimmune|ALT - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku altimmune.com|ALT - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

- data bathi bisnis lan rasio investasi:

ALT - Penghasilan resik|Bathi sing dikarepake Altimmune, Inc.|ALT - Koefisien rega marang bathi|Prakiraan rega marang bathi Altimmune Corp|ALT - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Altimmune Pharma|ALT - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Altimmune|ALT - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan altimmune.com|ALT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Altimmune, Inc.

- indikator volume dodolan lan pendapatan:

ALT - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan Altimmune|ALT - Rasio kapitalisasi marang pendapatan|Multiplikator Forward P/S Altimmune Pharma

Ringkesan analitik perusahaan:Altimmune (ALT)

The forward P/S ratio assesses the market value of Altimmune, Inc. (ALT) relative to expected sales volume, determining demand resilience and the risk of a "value trap" during price declines. Analyzing the expected price-to-sales ratio allows for an assessment of the probability of Pemvidutide's commercial success and the willingness of strategic partners to invest in scaling the business of Altimmune, Inc. (ALT) amid macroeconomic volatility.

Perusahaan pesaing